Download PDF

Register to download the report. Already a member?

 
 
Sign Up

Or

60275 1492790397HCLSReviewGreeceApril2017.pdf
Energy Boardroom

Cubist's Trius buyout pays off with FDA nod on high-powered antibiotic Sivextro

23.06.2014 / Fierce Pharma

Less than a year after Cubist scooped up Trius for $707 million in a bid to boost its presence in antibiotics, it can boast an FDA approval out of the deal. On Friday, the agency approved Sivextro, an antibacterial drug to treat a range of skin infections, including methicillin-resistant Staphylococcus aureus (MRSA).

LATEST ISSUE

DOWNLOAD

X
Download PDF

First Name:

Last Name:

Company:

Position:

Country:

Email: